Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia; Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia 61511, Egypt.
Int Immunopharmacol. 2023 Jun;119:110206. doi: 10.1016/j.intimp.2023.110206. Epub 2023 Apr 21.
Recently, there has been an uptick in reported cases of monkeypox (Mpox) in Africa and across the globe. This prompted us to investigate the efficacy of the two vaccines that can prevent Mpox, the modified vaccinia Ankara virus (MVA) vaccine and ACAM2000 vaccine. We analyzed them to determine their rates of humoral cell responses, adverse events, and rash reactions and used these factors as the primary indicators.
This study adapted primary data obtained from the Medline, Google Scholar, and Cochrane Library databases. We included a total of eight studies, three of which explored the ACAM2000 vaccine and five of which explored the JYNNEOS MVA vaccine.
There were significant differences in the rates of humoral responses after inoculation by the two vaccines. JYNNEOS MVA vaccine immunization resulted in a statistically significant increased humoral immune response with an effect size of 81.00 (42.80, 119.21) at a 95% CI and a rash reaction with an effect size of 96.50 (42.09, 235.09.21) at a 95% CI. ACAM2000 resulted in a lesser increase in neutralizing antibodies than JYNNEOS MVA vaccine. Similar findings were identified for the rates of adverse reactions, but the difference was not statistically significant. The differences in rash reaction rates in the two vaccination groups were also not statistically significant.
ACAM2000 and JYNNEOS vaccines have proven to be efficient in preventing Mpox even though variations exist in their modes of action and associated significant effects. The nonreplicating nature of JYNNEOS prevents the occurrence of the adverse effects seen with other vaccines.
最近，非洲和全球报告的猴痘 (Mpox) 病例有所增加。这促使我们研究两种可预防猴痘的疫苗，即改良安卡拉痘苗病毒（MVA）疫苗和 ACAM2000 疫苗的疗效。我们分析了它们以确定它们的体液细胞反应、不良事件和皮疹反应率，并将这些因素作为主要指标。
本研究改编自 Medline、Google Scholar 和 Cochrane Library 数据库的原始数据。我们共纳入了 8 项研究，其中 3 项研究了 ACAM2000 疫苗，5 项研究了 JYNNEOS MVA 疫苗。
两种疫苗接种后的体液反应率存在显著差异。JYNNEOS MVA 疫苗接种导致体液免疫反应呈统计学显著增加，效应大小为 81.00（42.80，119.21），95%CI 为 42.09，235.09.21）在 95%CI 内。ACAM2000 导致中和抗体的增加低于 JYNNEOS MVA 疫苗。不良反应发生率也存在类似的发现，但差异无统计学意义。两种疫苗接种组皮疹反应率的差异也无统计学意义。
尽管作用方式和相关显著影响存在差异，但 ACAM2000 和 JYNNEOS 疫苗已被证明能有效预防猴痘。JYNNEOS 的非复制性质可防止其他疫苗出现不良反应。
Zotero 插件
